Skip to main content
. 2016 Aug 8;8(22):949–956. doi: 10.4254/wjh.v8.i22.949

Table 3.

Adverse events (%) and treatment discontinuation

Adverse events (73.9%)
Anemia 52.9
Asthenia 39.6
Neutro/thrombopenia 29.6
Dysgeusia 8.6
Psychiatric disorders 6.7
Anorectal symptoms 5.9
Others (see text) 14.9
Treatment discontinuation (122 cases; 14.6%) Number of cases
Rash/Itch 36 (29.5%)
Anemia 28 (22.9%)
Asthenia 18 (14.7%)
Psychiatric disorders 6 (5%)
Pancytopenia 3 (2.5%)
Neutro/thrombopenia 3 (2.5%)
Others (see text) 28 (22.9%)